Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clofazimine

FDA-approved product (capsule, oral), marketed as Lamprene.

Registered studies
50+
Lab records
5
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clofazimine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Leprosy

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Drugs for treatment of lepra
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04BA01; FDA class Antimycobacterial

Repurposing investigation

Clofazimine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis78.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 5 of 5 lab records
Open Clofazimine in ChEMBL Registered studies below
Show the 5 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clofazimine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

    NCT04311502 · start 2021-11-05

    Registered record
    Registry ID
    NCT04311502
    Conditions
    HIV; Tuberculosis
    Interventions
    Rifapentine; Rifampicin; Isoniazid; Pyrazinamide; Ethambutol; Clofazimine loading dose; Clofazimine 100 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-11-05
    Completion
    2025-06-24
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionRifapentine; Rifampicin; Isoniazid; Pyrazinamide +3 more
    PhasePhase 2
    Registry statusTerminated

  • A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB

    NCT05278988 · start 2021-04-01

    Registered record
    Registry ID
    NCT05278988
    Conditions
    MDR-TB
    Interventions
    PRS Regimen V; MDR-TB Treatment Regimen(WHO)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2024-10-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDR-TB
    InterventionPRS Regimen V; MDR-TB Treatment Regimen(WHO)
    PhasePhase 4
    Registry statusCompleted

  • Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)

    NCT04670120 · start 2021-03-01

    Registered record
    Registry ID
    NCT04670120
    Conditions
    Sensitive Pulmonary Tuberculosis
    Interventions
    Pyrifazimine (TBI-166)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-03-01
    Completion
    2021-12-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSensitive Pulmonary Tuberculosis
    InterventionPyrifazimine (TBI-166)
    PhasePhase 2
    Registry statusUnknown

  • Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

    NCT04717908 · start 2021-01-20

    Registered record
    Registry ID
    NCT04717908
    Conditions
    Multidrug Resistant Tuberculosis
    Interventions
    Bedaquiline; Pyrazinamide; Linezolid; Cycloserine; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-20
    Completion
    2024-06-22
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Tuberculosis
    InterventionBedaquiline; Pyrazinamide; Linezolid; Cycloserine +1 more
    PhaseNot applicable
    Registry statusCompleted

  • RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

    NCT04616924 · start 2020-12-01

    Registered record
    Registry ID
    NCT04616924
    Conditions
    Pulmonary Mycobacterium Avium Complex Infection; Bronchiectasis; Lung Diseases
    Interventions
    RHB-204; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-12-01
    Completion
    2023-08-28
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Mycobacterium Avium Complex Infection; Bronchiectasis; Lung Diseases
    InterventionRHB-204; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Economic Evaluation of New MDR TB Regimens

    NCT04207112 · start 2020-10-20

    Registered record
    Registry ID
    NCT04207112
    Conditions
    Multi-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculoses
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine; Standard Drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-10-20
    Completion
    2022-08-25
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculoses
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

    NCT04465695 · start 2020-07-14

    Registered record
    Registry ID
    NCT04465695
    Conditions
    COVID-19
    Interventions
    Interferon beta-1b; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-07-14
    Completion
    2021-09-30
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionInterferon beta-1b; Clofazimine
    PhasePhase 2
    Registry statusUnknown

  • Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

    NCT03867136 · start 2020-06-01

    Registered record
    Registry ID
    NCT03867136
    Conditions
    Multidrug Resistant Tuberculosis
    Interventions
    PZA sensitivity guided ultra-short all Oral Regimen; Standardized Shorter Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-06-01
    Completion
    2024-08-10
    Enrolment
    354

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Tuberculosis
    InterventionPZA sensitivity guided ultra-short all Oral Regimen; Standardized Shorter Regimen
    PhasePhase 4
    Registry statusCompleted

  • Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

    NCT03896685 · start 2020-04-06

    Registered record
    Registry ID
    NCT03896685
    Conditions
    Tuberculosis, Multidrug-Resistant; Tuberculosis; Pulmonary Tuberculoses; Mycobacterial Infections; Bacterial Infections; Gram-Positive Bacterial Infections
    Interventions
    Bedaquiline 100 MG; Delamanid 50 MG Oral Tablet; Clofazimine 100 MG Oral Capsule; Linezolid 600Mg Tab; Control arm MDR-TB regimen, designed according to latest WHO guidelines
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-04-06
    Completion
    2024-12-31
    Enrolment
    323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant; Tuberculosis; Pulmonary Tuberculoses; Mycobacterial Infections +2 more
    InterventionBedaquiline 100 MG; Delamanid 50 MG Oral Tablet; Clofazimine 100 MG Oral Capsule; Linezolid 600Mg Tab +1 more
    PhasePhase 3
    Registry statusCompleted

  • Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

    NCT04310930 · start 2020-03-02

    Registered record
    Registry ID
    NCT04310930
    Conditions
    Pulmonary Disease Due to Mycobacteria (Diagnosis)
    Interventions
    Amikacin; Tigecycline; Imipenem; Cefoxitin; Azithromycin; Clarithromycin; Clofazimine; Ethambutol; Amikacin; Linezolid; co-trimoxazole; Doxycycline; Moxifloxacin; Bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2020-03-02
    Completion
    2030-06-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease Due to Mycobacteria (Diagnosis)
    InterventionAmikacin; Tigecycline; Imipenem; Cefoxitin +11 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

    NCT04062201 · start 2019-08-22

    Registered record
    Registry ID
    NCT04062201
    Conditions
    Tuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis; Multi Drug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis
    Interventions
    Bedaquiline Oral Tablet; Linezolid Oral Tablet; Delamanid in Oral Dosage Form; Clofazimine Oral Product; Levofloxacin Oral Tablet; Isoniazid Oral Product; Ethambutol Oral Product; Pyrazinamide Oral Product; Linezolid Oral Tablet; Clofazimine Oral Product; Levofloxacin Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-08-22
    Completion
    2024-04-15
    Enrolment
    402

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis; Multi Drug Resistant Tuberculosis +1 more
    InterventionBedaquiline Oral Tablet; Linezolid Oral Tablet; Delamanid in Oral Dosage Form; Clofazimine Oral Product +7 more
    PhasePhase 3
    Registry statusCompleted

  • PRACTECAL-PKPD Sub Study

    NCT04081077 · start 2019-08-06

    Registered record
    Registry ID
    NCT04081077
    Conditions
    Multi-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculosis
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-08-06
    Completion
    2022-09-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculosis
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +1 more
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT03830671 · start 2019-03-08

    Registered record
    Registry ID
    NCT03830671
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    18-month regimen containing 6 anti-TB drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-08
    Completion
    2022-06-08
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    Intervention18-month regimen containing 6 anti-TB drugs
    PhasePhase 4
    Registry statusCompleted

  • Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

    NCT03474198 · start 2018-03-21

    Registered record
    Registry ID
    NCT03474198
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Rifampicin; Isoniazid; Pyrazinamide; Ethambutol; Linezolid; Clofazimine; Rifapentine; Levofloxacin; Bedaquiline; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-03-21
    Completion
    2022-01-20
    Enrolment
    675

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionRifampicin; Isoniazid; Pyrazinamide; Ethambutol +6 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis

    NCT03341767 · start 2017-12-14

    Registered record
    Registry ID
    NCT03341767
    Conditions
    Cryptosporidiosis
    Interventions
    Clofazimine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-12-14
    Completion
    2019-07-05
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptosporidiosis
    InterventionClofazimine; Placebo
    PhasePhase 2
    Registry statusTerminated